Bei-Lei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bei-Lei Liu has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Xin-Yuan Guan
MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou 510632, China
29 shared publications - Bai-Feng Zhang
Department of Clinical Oncology, The University of Hong Kong
23 shared publications - Lan-Qi Gong
Department of Clinical Oncology State Key Laboratory for Liver Research The University of Hong Kong Hong Kong China
22 shared publications - Xiao-Na Fang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
22 shared publications - Ching Ngar Wong
Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
21 shared publications - Shan Liu
Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
21 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Advanced Science
Histone Chaperone ASF1B Promotes Progenitor‐Like Cell States in Hepatocellular Carcinoma Through H3.3‐Dependent SOX9 Transcriptional Activation
Background and Aims: Tumor plasticity contributes to hepatocellular carcinoma (HCC) progression and therapy resistance, but chromatin mechanisms underlying progenitor‐like malignant cell states remain incompletely defined. This study investigates whether ASF1B functions as an oncofetal chromatin regulator of these states in HCC. Approach and Results: Integration of a human hepatocyte differentiation model with clinical and single‐cell datasets identifies ASF1B as an oncofetal histone chaperone reactivated in HCC and associated with poor differentiation and unfavorable survival. Functional analyses show that ASF1B promotes progenitor‐ and stemness‐associated properties, favors less‐differentiated malignant cell states, and enhances tumor growth, metastatic phenotypes, and sorafenib resistance. Mechanistically, ASF1B interacts with histone H3.3, increases H3.3 enrichment and RNA polymerase II engagement at the SOX9 promoter, and enhances nascent SOX9 transcription, with HIRA contributing to replication‐independent H3.3 deposition. ASF1B and H3.3 also exhibit dynamic co‐condensation in live cells and a reconstituted system. Genetic epistasis establishes SOX9 as a major downstream effector. Liver‐directed ASF1B depletion reduces tumor burden and enhances sorafenib responsiveness in an immunocompetent HCC model. Conclusions: ASF1B promotes progenitor‐like malignant cell states through an H3.3‐SOX9 chromatin regulatory axis and represents a candidate therapeutic vulnerability in HCC. ASF1B and H3.3 additionally exhibit dynamic co‐condensation, suggesting a possible biophysical feature.
- 15 November 2026
- Published by Wiley in Advanced Science
Open AccessHistone Chaperone ASF1B Promotes Progenitor‐Like Cell States in Hepatocellular Carcinoma Through H3.3‐Dependent SOX9 Transcriptional Activation
Background and Aims: Tumor plasticity contributes to hepatocellular carcinoma (HCC) progression and therapy resistance, but chromatin mechanisms underlying progenitor‐like malignant cell states remain incompletely defined. This study investigates whether ASF1B functions as an oncofetal chromatin regulator of these states in HCC. Approach and Results: Integration of a human hepatocyte differentiation model with clinical and single‐cell datasets identifies ASF1B as an oncofetal histone chaperone reactivated in HCC and associated with poor differentiation and unfavorable survival. Functional analyses show that ASF1B promotes progenitor‐ and stemness‐associated properties, favors less‐differentiated malignant cell states, and enhances tumor growth, metastatic phenotypes, and sorafenib resistance. Mechanistically, ASF1B interacts with histone H3.3, increases H3.3 enrichment and RNA polymerase II engagement at the SOX9 promoter, and enhances nascent SOX9 transcription, with HIRA contributing to replication‐independent H3.3 deposition. ASF1B and H3.3 also exhibit dynamic co‐condensation in live cells and a reconstituted system. Genetic epistasis establishes SOX9 as a major downstream effector. Liver‐directed ASF1B depletion reduces tumor burden and enhances sorafenib responsiveness in an immunocompetent HCC model. Conclusions: ASF1B promotes progenitor‐like malignant cell states through an H3.3‐SOX9 chromatin regulatory axis and represents a candidate therapeutic vulnerability in HCC. ASF1B and H3.3 additionally exhibit dynamic co‐condensation, suggesting a possible biophysical feature.
- Open Access
- 16 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
GPRC5A promotes lung colonization of esophageal squamous cell carcinoma
Emerging evidence suggests that cancer cells may disseminate early, prior to the formation of traditional macro-metastases. However, the mechanisms underlying the seeding and transition of early disseminated cancer cells (DCCs) into metastatic tumors remain poorly understood. Through single-cell RNA sequencing, we show that early lung DCCs from esophageal squamous cell carcinoma (ESCC) exhibit a trophoblast-like ‘tumor implantation’ phenotype, which enhances their dissemination and supports metastatic growth. Notably, ESCC cells overexpressing GPRC5A demonstrate improved implantation and persistence, resulting in macro-metastases in the lungs. Clinically, elevated GPRC5A level is associated with poorer outcomes in a cohort of 148 ESCC patients. Mechanistically, GPRC5A is found to potentially interact with WWP1, facilitating the polyubiquitination and degradation of LATS1, thereby activating YAP1 signaling pathways essential for metastasis. Importantly, targeting YAP1 axis with CA3 or TED-347 significantly diminishes early implantation and macro-metastases. Thus, the GPRC5A/WWP1/LATS1/YAP1 pathway represents a crucial target for therapeutic intervention in ESCC lung metastases.
- 16 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessGPRC5A promotes lung colonization of esophageal squamous cell carcinoma
Emerging evidence suggests that cancer cells may disseminate early, prior to the formation of traditional macro-metastases. However, the mechanisms underlying the seeding and transition of early disseminated cancer cells (DCCs) into metastatic tumors remain poorly understood. Through single-cell RNA sequencing, we show that early lung DCCs from esophageal squamous cell carcinoma (ESCC) exhibit a trophoblast-like ‘tumor implantation’ phenotype, which enhances their dissemination and supports metastatic growth. Notably, ESCC cells overexpressing GPRC5A demonstrate improved implantation and persistence, resulting in macro-metastases in the lungs. Clinically, elevated GPRC5A level is associated with poorer outcomes in a cohort of 148 ESCC patients. Mechanistically, GPRC5A is found to potentially interact with WWP1, facilitating the polyubiquitination and degradation of LATS1, thereby activating YAP1 signaling pathways essential for metastasis. Importantly, targeting YAP1 axis with CA3 or TED-347 significantly diminishes early implantation and macro-metastases. Thus, the GPRC5A/WWP1/LATS1/YAP1 pathway represents a crucial target for therapeutic intervention in ESCC lung metastases.
- Top Cited PapersOpen Access
- 17 July 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-44
Exploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort and the potential to impede disease progression. Nonetheless, it is acknowledged that these therapeutic strategies still harbour untapped potential for further advancement. Gaining a comprehensive understanding of the merits and limitations of these treatment modalities holds the promise of offering novel perspectives for clinical practice and foundational research endeavours. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. It will provide a detailed explanation of each method, addressing their status of development, clinical challenges, and potential solutions. The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.
- 17 July 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-44
Top Cited PapersOpen AccessExploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy. These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort and the potential to impede disease progression. Nonetheless, it is acknowledged that these therapeutic strategies still harbour untapped potential for further advancement. Gaining a comprehensive understanding of the merits and limitations of these treatment modalities holds the promise of offering novel perspectives for clinical practice and foundational research endeavours. In this review, we discussed the different treatment modalities, including small molecule targeted drugs, peptide drugs, antibody drugs, cell therapy, and gene therapy. It will provide a detailed explanation of each method, addressing their status of development, clinical challenges, and potential solutions. The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.